Absci, PrecisionLife collaborate to develop novel biotherapeutics for chronic diseases
Absci (Nasdaq: ABSI), a generative AI drug creation company, and PrecisionLife, a leader in computational biology, today announced a significant collaboration. This partnership is set to develop a portfolio of potential therapeutics, targeting unmet medical needs in chronic diseases. The collaboration leverages Absci’s prowess in antibody design and PrecisionLife’s expertise in complex disease biology, aiming […]